OB Pharmaceuticals began operations in 2014 to undertake the research and development of a new class of molecules that show promise for the treatment of epilepsy and brain injury related seizures.
Epilepsy is a chronic neurological spectrum disorder affecting nearly 65 million people worldwide and is characterized by recurrent and often debilitating seizures. More than 30% become drug resistant.
A seizure is abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and / or involuntary muscle movements.

Latest from the Blog